BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 12, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 4, 2015
View Archived Issues
Chong Kun Dang Holdings reports HDAC6 inhibitors
Read More
Beaufour Ipsen Tianjin Pharmaceutical reports androgen receptor degradation enhancers
Read More
Telotristat etiprate achieves primary endpoint in phase III trial in carcinoid syndrome
Read More
Bayer starts pilot study of BAY-1142524 in left ventricular dysfunction after MI
Read More
rVZV-ZEBOV Ebola vaccine up to 100% effective, interim results of West African trial indicate
Read More
Cancer antigen-125 levels, a potential biomarker of long-term mortality in COPD
Read More
ContraVir Pharmaceuticals enrolls first patient in pivotal phase III trial of FV-100
Read More
Bristol-Myers Squibb patents lipase inhibitors
Read More
Amgen highlights milestones from second quarter 2015
Read More
Merck & Co. discloses ROMK channel blockers
Read More
Analytical Services develops polyphenol conjugates for cancer
Read More
ADMA Biologics files BLA for immune globulin RI-002
Read More
Cidara Therapeutics begins phase I study of CD-101 IV
Read More
Clovis Oncology completes regulatory submissions for Rociletinib
Read More
Omidria approved in the E.U.
Read More
Dermira begins phase III program in axillary hyperhidrosis for DRM-04
Read More
biOasis's MTfp-I2S effective in mouse model of Hunter syndrome
Read More
BMS joins immuno-oncology initiative for high-risk cancers
Read More
Shire acquires Foresight Biotherapeutics and gains phase II conjunctivitis drug
Read More
Formula Pharmaceuticals licenses rights to transposon-based gene transfer technology
Read More
Charleston Laboratories begins enrollment in a phase I study of CL-H1T
Read More
Amarantus partners with U.S. Army and Rutgers University to develop skin replacement
Read More
Protalix's oral anti-TNF fusion protein safe and well tolerated in phase I trial
Read More
Abbott makes deals with heart valve device developers Tendyne and Cephea
Read More
Io Therapeutics partners with the National Multiple Sclerosis Society
Read More